{"transactions":[{"id":3003145,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214281},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003144,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1390376,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1390376},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003143,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1917157,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003142,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1604657,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003141,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1390376,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1390376,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3109260,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T17:42:29.000Z","date":"2020-06-12","kind":"other","acquired":false,"shares":1456854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution in-kind by Frazier Life Sciences IX, L.P. (\"FLS IX\") to its limited partners for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents shares held of record by FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5827415,"source":{"system":"sec-edgar","filing":"0001209191-20-037031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120037031/doc4.xml","form_type":"4"}},{"id":3233208,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":432802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":432802},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233207,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":1049175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049175},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233206,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":2977242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2977242},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233205,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":550000,"price":18,"value":9900000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5009219,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233204,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":432802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":4459219,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233203,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":1049175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":4026417,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233202,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":2977242,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2977242,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3385431,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":4,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":5,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Notes","published_at":"2019-10-30T17:04:17.000Z","date":"2019-10-29","kind":"exercise","acquired":false,"reported_value":20575342.48,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences IX, L.P. (\"FLS IX\"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2020-05-07","underlying":"Common Stock","underlying_shares":1353640},"source":{"system":"sec-edgar","filing":"0001209191-19-054525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119054525/doc4.xml","form_type":"4"}},{"id":3385430,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":4,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":5,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-30T17:04:17.000Z","date":"2019-10-29","kind":"purchase","acquired":true,"shares":1052631,"price":19,"value":19999989.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences IX, L.P. (\"FLS IX\"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":7284269,"source":{"system":"sec-edgar","filing":"0001209191-19-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119054525/doc4.xml","form_type":"4"}},{"id":3385429,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":4,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":5,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-30T17:04:17.000Z","date":"2019-10-29","kind":"exercise","acquired":true,"shares":1353640,"price":15.2,"value":20575328.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences IX, L.P. (\"FLS IX\"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":6231638,"source":{"system":"sec-edgar","filing":"0001209191-19-054525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119054525/doc4.xml","form_type":"4"}},{"id":3456814,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-07-24T16:17:33.000Z","date":"2019-07-22","kind":"exercise","acquired":false,"shares":24935300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX,\nL.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C.\nand share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial\nownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3116912},"source":{"system":"sec-edgar","filing":"0001209191-19-043024","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119043024/doc4.xml","form_type":"4"}},{"id":3456813,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-24T16:17:33.000Z","date":"2019-07-22","kind":"purchase","acquired":true,"shares":450000,"price":15,"value":6750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX,\nL.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C.\nand share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial\nownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":3566912,"source":{"system":"sec-edgar","filing":"0001209191-19-043024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119043024/doc4.xml","form_type":"4"}},{"id":3456812,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-24T16:17:33.000Z","date":"2019-07-22","kind":"exercise","acquired":true,"shares":3116912,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX,\nL.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C.\nand share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial\nownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":3116912,"source":{"system":"sec-edgar","filing":"0001209191-19-043024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119043024/doc4.xml","form_type":"4"}}]}